Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firdapse pharmacokinetic and safety study in healthy volunteers
NL-OMON36156Phase 1Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amifampridine in Lambert-Eaton myasthenic syndrome (LEMS), sponsored by BioMarin Pharmaceutical Inc. Primary endpoints: Safety and tolerability of Firdapse after single and multiple doses and Pharmacokinetics. Started Mar 2011; status: active, not recruiting.
02
Drugs
amifampridine
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on NL-OMON36156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36156.